Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov;63(11):1189-1193.
doi: 10.1007/s00108-022-01377-x. Epub 2022 Aug 24.

[Rhabdomyolysis due to drug-drug interaction of atorvastatin and cobicistat]

[Article in German]
E Intert  1 , M Krause  2 , F Hennersdorf  2 , K Knop  3 , T Rosenkranz  3
Affiliations
Case Reports

[Rhabdomyolysis due to drug-drug interaction of atorvastatin and cobicistat]

[Article in German]
E Intert et al. Inn Med (Heidelb). 2022 Nov.

Abstract
in English, German

A 53-year-old man presented with rhabdomyolysis and acute kidney injury. The symptoms were presumably caused by a drug-drug interaction between an antiretroviral drug combination and atorvastatin. As a booster, cobicistat can also increase the toxicity of statins via inhibition of the enzyme cytochrome p450 3A4 (CYP3A4). After stopping atorvastatin and after intravenous fluid therapy, the symptoms regressed completely.

Ein 53-jähriger Patient wurde mit Rhabdomyolyse und akutem Nierenversagen vorstellig. Als Ursache ist eine Arzneimittelinteraktion der antiretroviralen Kombination mit Atorvastatin anzunehmen. Cobicistat kann als Booster über eine Hemmung des Enzyms Cytochrom P450 3A4 (CYP3A4) auch die Toxizität von Statinen steigern. Nach Absetzen von Atorvastatin sowie forcierter Volumentherapie kam es zu einer vollständigen Regredienz der Beschwerden.

Keywords: Cytochrome P450 3A4 (CYP3A4); HIV; High active anti-retroviral therapy (HAART); Myopathy; Statins.

PubMed Disclaimer

Similar articles

See all similar articles

References

Literatur

    1. Aberg JA et al (2017) Pitavastatin versus pravastatin in adults with HIV‑1 infection and dyslipidaemia (INTREPID). Lancet HIV 4:e284–e294. https://doi.org/10.1016/S2352-3018(17)30075-9 - DOI - PubMed
    1. Brunham et al (2018) Role of genetics in the prediction of statin-Associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res 114:1073–1081. https://doi.org/10.1093/cvr/cvy119 - DOI - PubMed - PMC
    1. Burger et al (2020) Cobicistat: a case of mislabelled drug-drug interaction risk? Br J Clin Pharmacol 86:834–836. https://doi.org/10.1111/bcp.14262 - DOI - PubMed - PMC
    1. Eshraghian et al (2013) Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis. Intern Med 52:823–825. https://doi.org/10.2169/internalmedicine.52.9272 - DOI - PubMed
    1. Mach F et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188. https://doi.org/10.1093/eurheartj/ehz455 - DOI - PubMed

LinkOut - more resources